WO2011056325A2 - Conjugués oligomère-calcimimétique et composés associés - Google Patents

Conjugués oligomère-calcimimétique et composés associés Download PDF

Info

Publication number
WO2011056325A2
WO2011056325A2 PCT/US2010/050761 US2010050761W WO2011056325A2 WO 2011056325 A2 WO2011056325 A2 WO 2011056325A2 US 2010050761 W US2010050761 W US 2010050761W WO 2011056325 A2 WO2011056325 A2 WO 2011056325A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
compound
group
oligomer
soluble
Prior art date
Application number
PCT/US2010/050761
Other languages
English (en)
Other versions
WO2011056325A3 (fr
Inventor
Jennifer Riggs-Sauthier
Lin Cheng
David Martin
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012531124A priority Critical patent/JP5792175B2/ja
Priority to KR1020127005885A priority patent/KR101828613B1/ko
Priority to EP10810996.8A priority patent/EP2482855B1/fr
Priority to CA2773353A priority patent/CA2773353C/fr
Priority to CN201080043400.0A priority patent/CN102573921B/zh
Priority to AU2010315805A priority patent/AU2010315805B2/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority to MX2012003775A priority patent/MX341690B/es
Publication of WO2011056325A2 publication Critical patent/WO2011056325A2/fr
Publication of WO2011056325A3 publication Critical patent/WO2011056325A3/fr
Priority to IL218869A priority patent/IL218869A/en
Priority to US13/433,100 priority patent/US8722732B2/en
Priority to US14/223,572 priority patent/US9421275B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
    • C07F3/04—Calcium compounds

Definitions

  • This invention comprises (among other things) conjugates of a calcimimetic that possess certain advantages over the calcimimetic in unconjugated form.
  • the conjugates (also referred to as “inventive compounds” and “compounds of the invention”) described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
  • Calcimimetics are small molecule drugs that mimic the action of calcium on tissues through allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.
  • calcimimetics are used to treat patients suffering from hyperparathyroidism, often caused by parathyroid cancers and chronic renal failure.
  • a calcimimetic available commercially is (a/?)-(-)-a-methyl-N-[3-[3- [trifluoromethylphenyl]propyl]-1-napthalenemethanamine or cinacalcet, sold as the
  • calcimimetics are a class of orally active, small molecules that decrease the secretion of parathyroid hormone (PTH) by activating calcium receptors.
  • the secretion of parathyroid hormone is normally regulated by the calcium-sensing receptor.
  • Calcimimetics increase the sensitivity of this receptor to calcium, which inhibits the release of parathyroid hormone, thereby lowering parathyroid hormone levels within a few hours.
  • cinacalcet is an inhibitor of CYP2D6, which can increase the blood concentration of drugs metabolized by CYP2D6.
  • cinacalcet is typically administered at least once daily, wheren a less frequent dose (e.g., once a week dosing) would allow for a more convenient regimen.
  • calcimimetic with a half-life longer than cinacalcet's 30 to 40 hours would avoid potential hypocalcemia and other risks associated with a reduced Cmax and/or greater time away from the Cmax. Reduction of one or more of these side effects from calcimimetics would enhance their desirability as therapeutic drugs.
  • a compound comprising a calcimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer, and pharmaceutically acceptable acid addition salts or complexes thereof.
  • Compositions of enantiomers of the calcimimetic are also contemplated wherein the composition comprises one enantiomer in an amount greater than the other (e.g., one enantiomer is substantially present in the composition and the other enantiomer is substantially absent in the composition), wherein R enantiomers are preferred.
  • Exemplary compounds of the invention include those compounds comprising a calicimimetic residue covalently attached via a stable or releasable linkage to a
  • Exemplary compounds of the invention include those having the following structure:
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -NO 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)0CH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(
  • (a) is an integer from 1 to 5;
  • R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -NO2, -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alkyl (e
  • (a) is an integer from 1 to 5;
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH2CF 3 , -OH, -CN, -NO 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alkyl (
  • (a) is an integer from 1 to 5;
  • R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -NO 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)O-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • the "calcimimetic residue” is a compound having a structure of a calcimimetic that is altered by the presence of one or more bonds, which bonds serve to attach (either directly or indirectly) one or more water-soluble, non-peptidic oligomers.
  • any compound that is a calcimimetic can be used as a calcimimetic.
  • Preferred calcimimetics are described in U.S. Patent No. 6,01 1 ,068.
  • Exemplary calcimimetic moieties have a structure encompassed by Formula I:
  • alk is selected from the group consisting of n-propylene, 2,4-butylene and 1 ,3- butylene;
  • R 1 is selected from the group consisting of lower alkyl of from 1 to 3 carbon atoms and lower haloalkyl of from 1 to 3 carbon atoms substituted with from 1 to 7 halogen atoms;
  • R 2 and R 3 are independently selected monocyclic or bicyclic carbocyclic aryl or cycloalkyl groups, having 5- to 7-membered rings optionally substituted with 1 to 5 substituents independently selected from the group consisting of: OCF 3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms; and
  • R 2 is phenyl
  • said phenyl R 2 has at least one substituent that is not 4-OH-phenyl.
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -N0 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • (a) is an integer from 1 to 5;
  • R 5 is lower alkyl (e.g., methyl).
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms.
  • composition comprising a compound comprising a calcimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer, and optionally, a pharmaceutically acceptable excipient.
  • a dosage form comprising a compound comprising a calcimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer, wherein the compound is present in a dosage form.
  • a method comprising covalently attaching a water-soluble, non-peptidic oligomer to a calcimimetic.
  • a method comprising administering a compound comprising a calcimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer.
  • FIG. 1A and FIG. IB are each graphs showing plasma concentration-time profiles for exemplary compounds and released cinacalcet from exemplary compounds, as further described in Example 14.
  • FIG. 2 is a graph showing plasma concentration-time profiles for exemplary compounds and released cinacalcet from the exemplary compounds, as further described in Example 14.
  • FIG. 3 is a graph showing plasma concentration-time profiles for exemplary compounds and released cinacalcet from the exemplary compounds, as further described in Example 14.
  • FIG. 4 is a graph showing plasma concentration-time profiles for exemplary compounds and released cinacalcet from the exemplary compound, as further described in Example 14.
  • FIG. 5 is a graph showing plasma concentration-time profiles for exemplary compounds and released cinacalcet from the exemplary compound, as further described in Example 14.
  • FIG. 6 is a graph of rat plasma PTH levels following administration of cinacalcet (l Omg/kg, po) and exemplary compounds (lmg/kg, IV), as further described in Example 17.
  • FIG. 7 is a graph of rat plasma PTH levels following administration of cinacalcet (lOmg/kg, po) and exemplary compounds (lmg/kg, IV), as further described in Example 17.
  • FIG. 8 is a graph of rat plasma PTH levels following administration of cinacalcet (l Omg/kg, po) and exemplary compounds (lmg/kg, IV), as further described in Example 17.
  • FIG. 9 is a graph of rat plasma PTH levels following administration of cinacalcet (lOmg/kg, po) and exemplary compounds (lmg/kg, IV), as further described in Example 17.
  • Water soluble, non-peptidic oligomer indicates an oligomer that is at least
  • an unfiltered aqueous preparation of a "water-soluble" oligomer transmits at least 75%, more preferably at least 95%, of the amount of light transmitted by the same solution after filtering. It is most preferred, however, that the water-soluble oligomer is at least 95% (by weight) soluble in water or completely soluble in water.
  • an oligomer is non-peptidic when it has less than 35% (by weight) of amino acid residues.
  • the terms "monomer,” “monomeric subunit” and “monomeric unit” are used interchangeably herein and refer to one of the basic structural units of a polymer or oligomer.
  • a homo-oligomer a single repeating structural unit forms the oligomer.
  • two or more structural units are repeated ⁇ either in a pattern or randomly— to form the oligomer.
  • Preferred oligomers used in connection with present the invention are homo-oligomers.
  • the water-soluble, non-peptidic oligomer typically comprises one or more monomers serially attached to form a chain of monomers.
  • the oligomer can be formed from a single monomer type (i.e., is homo-oligomeric) or two or three monomer types (i.e., is co-oligomeric).
  • oligomer is a molecule possessing from about 1 to about 30 monomers.
  • oligomers for use in the invention include those having a variety of geometries such as linear, branched, or forked, to be described in greater detail below.
  • PEG polyethylene glycol
  • polyethylene glycol is meant to encompass any water-soluble poly( ethylene oxide).
  • a "PEG oligomer” or an oligoethylene glycol is one in which substantially all (preferably all) monomeric subunits are ethylene oxide subunits, though the oligomer may contain distinct end capping moieties or functional groups, e.g., for conjugation.
  • PEG oligomers for use in the present invention will comprise one of the two following structures: "-(CH 2 CH 2 O) n -" or “-(CH 2 CH 2 O)n-iCH 2 CH 2 -,” depending upon whether or not the terminal oxygen(s) has been displaced, e.g., during a synthetic transformation.
  • the variable (n) ranges from 1 to 30, and the terminal groups and architecture of the overall PEG can vary.
  • PEG further comprises a functional group, A, for linking to, e.g., a small molecule drug
  • the functional group when covalently attached to a PEG oligomer does not result in formation of (i) an oxygen-oxygen bond (-0-0-, a peroxide linkage), or (ii) a nitrogen-oxygen bond (N-O, O-N).
  • end-capped or “terminally capped” are interchangeably used herein to refer to a terminal or endpoint of a polymer having an end-capping moiety.
  • the end-capping moiety comprises a hydroxy or C 1-2 o alkoxy group.
  • examples of end-capping moieties include alkoxy (e.g., methoxy, ethoxy and benzyloxy), as well as aryl, heteroaryl, cyclo, heterocyclo, and the like.
  • saturated, unsaturated, substituted and unsubstituted forms of each of the foregoing are envisioned.
  • the end-capping group can also be a silane.
  • the end-capping group can also advantageously comprise a detectable label.
  • the amount or location of the polymer and/or the moiety (e.g., active agent) of interest to which the polymer is coupled can be determined by using a suitable detector.
  • suitable detector include, without limitation, fluorescers,
  • chemiluminescers moieties used in enzyme labeling, colorimetric moieties (e.g., dyes), metal ions, radioactive moieties, and the like.
  • Suitable detectors include photometers, films, spectrometers, and the like.
  • the end-capping group may contain a targeting moiety.
  • targeting moiety is used herein to refer to a molecular structure that helps the conjugates of the invention to localize to a targeting area, e.g., help enter a cell, or bind a receptor.
  • the targeting moiety comprises of vitamin, antibody, antigen, receptor, DNA, RNA, sialyl Lewis X antigen, hyaluronic acid, sugars, cell specific lectins, steroid or steroid derivative, RGD peptide, ligand for a cell surface receptor, serum
  • the targeting moiety may also comprise a lipid or a phospholipid.
  • exemplary phospholipids include, without limitation, phosphatidylcholines, phospatidylserine, phospatidylinositol, phospatidylglycerol, and phospatidylethanolamine. These lipids may be in the form of micelles or liposomes and the like.
  • the targeting moiety may further comprise a detectable label or alternately a detectable label may serve as a targeting moiety. When the conjugate has a targeting group comprising a detectable label, the amount and/or
  • distribution/location of the polymer and/or the moiety (e.g. , active agent) to which the polymer is coupled can be determined by using a suitable detector.
  • suitable detector include, without limitation, fluorescers, chemiluminescers, moieties used in enzyme labeling, colorimetric (e.g., dyes), metal ions, radioactive moieties, gold particles, quantum dots, and the like.
  • Branched in reference to the geometry or overall structure of an oligomer, refers to an oligomer having two or more polymer "arms" extending from a branch point.
  • Formked in reference to the geometry or overall structure of an oligomer, refers to an oligomer having two or more functional groups (typically through one or more atoms) extending from a branch point.
  • a "branch point” refers to a bifurcation point comprising one or more atoms at which an oligomer branches or forks from a linear structure into one or more additional arms.
  • reactive refers to a functional group that reacts readily or at a practical rate under conventional conditions of organic synthesis. This is in contrast to those groups that either do not react or require strong catalysts or impractical reaction conditions in order to react (i.e., a "nonreactive” or "inert” group).
  • a "protecting group” is a moiety that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions.
  • the protecting group may vary depending upon the type of chemically reactive group being protected as well as the reaction conditions to be employed and the presence of additional reactive or protecting groups in the molecule.
  • Functional groups which may be protected include, by way of example, carboxylic acid groups, amino groups, hydroxyl groups, thiol groups, carbonyl groups and the like.
  • protecting groups for carboxylic acids include esters (such as a / methoxybenzyl ester), amides and hydrazides; for amino groups, carbamates (such as fcrf-butoxycarbonyl) and amides; for hydroxyl groups, ethers and esters; for thiol groups, thioethers and thioesters; for carbonyl groups, acetals and ketals; and the like.
  • Such protecting groups are well-known to those skilled in the art and are described, for example, in T.W. Greene and G.M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
  • a functional group in “protected form” refers to a functional group bearing a protecting group.
  • the term “functional group” or any synonym thereof encompasses protected forms thereof.
  • a "physiologically cleavable” or “hydrolyzable” or “degradable” bond is a relatively labile bond that reacts with water (i.e., is hydrolyzed) under physiological conditions.
  • the tendency of a bond to hydrolyze in water may depend not only on the general type of linkage connecting two central atoms but also on the substituents attached to these central atoms.
  • Appropriate hydrolytically unstable or weak linkages include but are not limited to carboxylate ester, phosphate ester, anhydrides, acetals, ketals, acyloxyalkyl ether, imines, orthoesters, peptides, oligonucleotides, thioesters, and carbonates.
  • An "enzymatically releasable linkage” means a linkage that is subject to degradation by one or more enzymes.
  • a “stable” linkage or bond refers to a chemical bond that is substantially stable in water, that is to say, does not undergo hydrolysis under physiological conditions to any appreciable extent over an extended period of time.
  • hydrolytically stable linkages include but are not limited to the following: carbon-carbon bonds (e.g., in aliphatic chains), ethers, amides, urethanes, amines, and the like.
  • a stable linkage is one that exhibits a rate of hydrolysis of less than about 1-2% per day under physiological conditions. Hydrolysis rates of representative chemical bonds can be found in most standard chemistry textbooks.
  • “Substantially” or “essentially” means nearly totally or completely, for instance, 95% or greater, more preferably 97% or greater, still more preferably 98% or greater, even more preferably 99% or greater, yet still more preferably 99.9% or greater, with 99.99% or greater being most preferred of some given quantity.
  • "Monodisperse” refers to an oligomer composition wherein substantially all of the oligomers in the composition have a well-defined, single molecular weight and defined number of monomers, as determined by chromatography or mass spectrometry.
  • Monodisperse oligomer compositions are in one sense pure, that is, substantially having a single and definable number (as a whole number) of monomers rather than a large distribution.
  • a monodisperse oligomer composition possesses a MW/Mn value of 1.0005 or less, and more preferably, a MW/Mn value of 1.0000.
  • a composition comprised of monodisperse conjugates means that substantially all oligomers of all conjugates in the composition have a single and definable number (as a whole number) of monomers rather than a large distribution and would possess a MW/Mn value of 1.0005, and more preferably, a MW/Mn value of 1.0000 if the oligomer were not attached to the calcimimetic.
  • a composition comprised of monodisperse conjugates may, however, include one or more nonconjugate substances such as solvents, reagents, excipients, and so forth.
  • Bimodal in reference to an oligomer composition, refers to an oligomer composition wherein substantially all oligomers in the composition have one of two definable and different numbers (as whole numbers) of monomers rather than a large distribution, and whose distribution of molecular weights, when plotted as a number fraction versus molecular weight, appears as two separate identifiable peaks.
  • each peak is generally symmetric about its mean, although the size of the two peaks may differ.
  • the polydispersity index of each peak in the bimodal distribution, Mw/Mn is 1.01 or less, more preferably 1.001 or less, and even more preferably 1.0005 or less, and most preferably a MW/Mn value of 1.0000.
  • a composition comprised of bimodal conjugates means that substantially all oligomers of all conjugates in the composition have one of two definable and different numbers (as whole numbers) of monomers rather than a large distribution and would possess a MW/Mn value of 1.01 or less, more preferably 1.001 or less and even more preferably 1.0005 or less, and most preferably a MW/Mn value of 1.0000 if the oligomer were not attached to the calcimimetic.
  • a composition comprised of bimodal conjugates may, however, incl ude one or more nonconjugate substances such as solvents, reagents, excipients, and so forth.
  • a "calcimimetic" refers to an organic, inorganic, or organometallic compound having a molecular weight of less than about 1000 Daltons and having some degree of calcimimetic activity. By using known assays, one of ordinary skill in the art will be able to determine whether any given compound has calcimimetic activity. Among the activities of a calcimimetic, increasing the sensitivity of the calcium-sensing receptor to activation by extracellular calcium is exemplary.
  • a “biological membrane” is any membrane made of cells or tissues that serves as a barrier to at least some foreign entities or otherwise undesirable materials.
  • a “biological membrane” includes those membranes that are associated with physiological protective barriers including, for example: the blood-brain barrier (BBB); the blood-cerebrospinal fluid barrier; the blood-placental barrier; the blood-milk barrier; the blood-testes barrier; and mucosal barriers including the vaginal mucosa, urethral mucosa, anal mucosa, buccal mucosa, sublingual mucosa, and rectal mucosa. Unless the context clearly dictates otherwise, the term “biological membrane” does not include those membranes associated with the middle gastro-intestinal tract (e.g., stomach and small intestines).
  • a "biological membrane crossing rate,” provides a measure of a compound's ability to cross a biological membrane, such as the blood-brain barrier ("BBB").
  • BBB blood-brain barrier
  • a variety of methods may be used to assess transport of a molecule across any given biological membrane.
  • Methods to assess the biological membrane crossing rate associated with any given biological barrier e.g., the blood-cerebrospinal fluid barrier, the blood-placental barrier, the blood-milk barrier, the intestinal barrier, and so forth), are known, described herein and/or in the relevant literature, and/or may be determined by one of ordinary skill in the art.
  • Alkyl refers to a hydrocarbon chain, ranging from about 1 to 20 atoms in length. Such hydrocarbon chains are preferably but not necessarily saturated and may be branched or straight chain. Exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, 2-methylbutyl, 2-ethylpropyl, 3-methylpentyl, and the like. As used herein, “alkyl” includes cycloalkyl when three or more carbon atoms are referenced.
  • “Lower alkyl” refers to an alkyl group containing from 1 to 6 carbon atoms, and may be straight chain or branched, as exemplified by methyl, ethyl, n-butyl, i-butyl, t- butyl.
  • Non-interfering substituents are those groups that, when present in a molecule, are typically non-reactive with other functional groups contained within the molecule.
  • Alkoxy refers to an -O-R group, wherein R is alkyl or substituted alkyl, preferably C 1-C20 alkyl (e.g., methoxy, ethoxy, propyloxy, benzyl, etc.), preferably C r C 7 .
  • “Pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” refers to a component that may be included in the compositions of the invention causing no significant adverse toxicological effects to a patient.
  • aryl means an aromatic group having up to 14 carbon atoms.
  • Aryl groups include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like.
  • Substituted phenyl and “substituted aryl” denote a phenyl group and aryl group, respectively, substituted with one, two, three, four or five (e.g., 1-2, 1-3 or 1-4 substituents) chosen from halo (F, CI, Br, I), hydroxy, hydroxy, cyano, nitro, alkyl (e.g., C 1-6 alkyl), alkoxy (e.g., Ci-6 alkoxy), benzyloxy, carboxy, aryl, and so forth.
  • halo F, CI, Br, I
  • alkyl e.g., C 1-6 alkyl
  • alkoxy e.g., Ci-6 alkoxy
  • benzyloxy carboxy, aryl, and so forth.
  • “Pharmacologically effective amount,” “physiologically effective amount,” and “therapeutically effective amount” are used interchangeably herein to mean the amount of a water-soluble oligomer-small molecule drug conjugate present in a composition that is needed to provide a desired level of active agent and/or conjugate in the bloodstream or in the target tissue.
  • the precise amount may depend upon numerous factors, e.g., the particular active agent, the components and physical characteristics of the composition, intended patient population, patient considerations, and may readily be determined by one skilled in the art, based upon the information provided herein and available in the relevant literature.
  • a "difunctional" oligomer is an oligomer having two functional groups contained therein, typically at its termini. When the functional groups are the same, the oligomer is said to be homodifunctional. When the functional groups are different, the oligomer is said to be heterobifunctional.
  • a basic reactant or an acidic reactant described herein include neutral, charged, and any corresponding salt forms thereof.
  • the term "patient,” refers to a living organism suffering from or prone to a condition that can be prevented or treated by administration of a conjugate as described herein, and includes both humans and animals.
  • the present invention is directed to (among other things) a compound comprising a calcimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer, and pharmaceutically acceptable acid addition salts or complexes thereof,
  • a compound comprising a calicimimetic residue covalently attached via a stable or releasable linkage to a water-soluble, non-peptidic oligomer, and pharmaceutically acceptable acid addition salt or complexes thereof, wherein the calcimimetic has the following structure:
  • alk is selected from the group consisting of n-propylene, 2,4-butylene and 1 ,3- butylene;
  • R 1 is selected from the group consisting of lower alkyl of from 1 to 3 carbon atoms and lower haloalkyl of from 1 to 3 carbon atoms substituted with from 1 to 7 halogen atoms;
  • R and R J are independently selected monocyclic or bicyclic carbocyclic aryl or cycloalkyl groups, having 5- to 7-membered rings optionally substituted with 1 to 5 substituents independently selected from the group consisting of: OCF 3 , lower alkyl of 1 to 3 carbon atoms, lower haloalkyl of 1 to 3 carbon atoms substituted with 1 to 7 halogen atoms, lower alkoxy of 1 to 3 carbon atoms, halogen, nitro, amino, alkylamino, amido, lower alkylamido of 1 to 3 carbon atoms, cyano, hydroxy, acyl of 2 to 4 carbon atoms, lower hydroxyalkyl of 1 to 3 carbon atoms, and lower thioalkyl of 1 to 3 carbon atoms; and
  • R 2 is phenyl
  • said phenyl R 2 has at least one substituent that is not 4-OH-phenyl.
  • ⁇ is selected from the group consisting of 3-methoxyphenyl, 3-chlorophenyl and 1 -naphthyl;
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -N0 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • (a) is an integer from 1 to 5;
  • R 5 is lower alkyl (e.g., methyl).
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms.
  • Calcimimetic moieties encompassed by Formulae I and II and other calcimimetics are described in U.S. Patent Nos. 6,01 1 ,068 and 6,21 1 ,244.
  • Approaches for preparing calcimimetics are described in U.S. Patent Nos. 7,563,930, 7,393,967, 7,250,533, 6,21 1 ,244, 6,01 1 ,068 5,648,541 and 4,966,988.
  • Exemplary compounds of the invention include those having the following structure:
  • ⁇ is selected from the group consisting of 3-methoxyphenyl, 3-chlorophenyl and 1 -naphthyl;
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -N0 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • (a) is an integer from 1 to 5; R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • ⁇ is selected from the group consisting of 3-methoxyphenyl, 3-chlorophenyl and 1-naphthyl;
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -N0 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • (a) is an integer from 1 to 5;
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • ⁇ is selected from the group consisting of 3-methoxyphenyl, 3-chlorophenyl and 1-naphthyl; each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -NO2, -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2
  • (a) is an integer from 1 to 5;
  • R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • each R 4 is independently selected from the group consisting of -H, -F, -CI, -Br, -I, phenyl, -CF 3 , -CF 2 H, -CFH 2 , lower alkyl (e.g., -CH 3 ), -O-lower alkyl (e.g., -OCH 3 ), -OCH 2 CF 3 , -OH, -CN, -N0 2 , -C(O)-lower alkyl (e.g., -C(O)CH 3 ), -C(O)0-lower alkyl (e.g., -C(O)OCH 3 ), -C(O)NH-lower alkyl (e.g., -C(O)NH-CH 3 ), -C(O)N-lower alkyl 2 (e.g., -C(O)N(CH 3 ) 2 ), -OC(O)-lower alky
  • (a') is an integer from 1 to 4;
  • R 5 is lower alkyl (e.g., methyl);
  • lower alkyl is selected from a group consisting of 1 to 6 carbon atoms
  • X is a spacer moiety (or "linkage”
  • POLY is a water-soluble, non-peptidic oligomer.
  • Use of oligomers e.g., from a monodisperse or bimodal composition of oligomers, in contrast to relatively impure compositions
  • oligomer-containing compounds can advantageously alter certain properties associated with the corresponding small molecule drug.
  • a compound of the invention when administered by any of a number of suitable administration routes, such as parenteral, oral, transdermal, buccal, pulmonary, or nasal, exhibits altered metabolism at CYP2D6.
  • the compounds of the invention maintain a degree of bioactivity as well as bioavailability in comparison to the bioactivity and bioavailability of the compound free of all oligomers.
  • Exemplary molecular weights of small molecule drugs serving as a calcimimetic include molecular weights of: less than about 950; less than about 900; less than about 850; less than about 800; less than about 750; less than about 700; less than about 650; less than about 600; less than about 550; less than about 500; less than about 450; less than about 400; less than about 350; and less than about 300, Daltons.
  • the small molecule drug (i.e., calcimimetic) used in the invention may be in a racemic mixture, or an optically active form, for example, a single optically active enantiomer, or any combination or ratio of enantiomers (i.e., scalemic mixture).
  • the small molecule drug may possess one or more geometric isomers.
  • a composition can comprise a single geometric isomer or a mixture of two or more geometric isomers.
  • a small molecule drug for use in the present invention can be in its customary active form, or may possess some degree of modification.
  • a small molecule drug may have a targeting agent, tag, or transporter attached thereto, prior to or after covalent attachment of an oligomer.
  • the small molecule drug may possess a lipophilic moiety attached thereto, such as a phospholipid (e.g.,
  • the calcimimetic for coupling to a water-soluble, non-peptidic oligomer possesses a free hydroxy!, carboxyl, thio, amino group, or the like (i.e., "handle") suitable for covalent attachment to the oligomer.
  • the calcimimetic can be modified by introduction of a reactive group, preferably by conversion of one of its existing functional groups to a functional group suitable for formation of a stable covalent linkage between the oligomer and the drug.
  • Amino groups on calicimetics provide a point of attachment between the calcimimetic and the oligomer.
  • oligomers activated with one or more functional groups that are useful for forming covalent linkages with available amines of a calcimimetics.
  • Table 1 Specific examples, along with the corresponding conjugate, are provided in Table 1 , below.
  • the variable (n) represents the number of repeating monomeric units and "-NH-(Cal)" represents the residue of the calcimimetic following conjugation to the oligomer. While each oligomeric portion [e.g., (OCH 2 CH 2 ) n or (CH2CH 2 O)n] presented in Table 1 terminates in a "CH 3 " group, other groups (such as H and benzyl) can be substituted therefor.
  • Conjugation of an oligomer to an amino group of a calcimimetic can be accomplished by a variety of techniques.
  • a calcimimetic can be conjugated to an oligomer functionalized with a succinimidyl derivative (or other activated ester or carbonate group, wherein approaches similar to those described for these alternative activated ester group-containing polymeric reagents can be used).
  • the oligomer bearing a succinimidyl derivative can be attached to the calcimimetic in an aqueous media at a pH of 7 to 9.0.
  • an amide linkage can be formed by reacting an amide linkage
  • each oligomer is composed of up to three different monomer types selected from the group consisting of: alkylene oxide, such as ethylene oxide or propylene oxide; olefinic alcohol, such as vinyl alcohol, 1-propenol or 2-propenol; vinyl pyrrolidone; hydroxyalkyl methacrylamide or hydroxyalkyl methacrylate, where alkyl is preferably methyl; a-hydroxy acid, such as lactic acid or glycolic acid; phosphazene, oxazoline, amino acids, carbohydrates such as monosaccharides, saccharide or mannitol; and N-acryloylmorpholine.
  • alkylene oxide such as ethylene oxide or propylene oxide
  • olefinic alcohol such as vinyl alcohol, 1-propenol or 2-propenol
  • vinyl pyrrolidone hydroxyalkyl methacrylamide or hydroxyalkyl methacrylate, where alkyl is preferably methyl
  • a-hydroxy acid such as lactic acid or
  • Preferred monomer types include alkylene oxide, olefinic alcohol, hydroxyalkyl methacrylamide or methacrylate, N-acryloylmorpholine, and a-hydroxy acid.
  • each oligomer is, independently, a co-oligomer of two monomer types selected from this group, or, more preferably, is a homo-oligomer of one monomer type selected from this group.
  • the two monomer types in a co-oligomer may be of the same monomer type, for example, two alkylene oxides, such as ethylene oxide and propylene oxide.
  • the oligomer is a homo-oligomer of ethylene oxide.
  • the terminus (or termini) of the oligomer that is not covalently attached to a small molecule is capped to render it unreactive.
  • the terminus may include a reactive group. When the terminus is a reactive group, the reactive group is either selected such that it is unreactive under the conditions of formation of the final oligomer or during covalent attachment of the oligomer to a small molecule drug, or it is protected as necessary.
  • One common end-functional group is hydroxyl or -OH, particularly for oligoethylene oxides.
  • the water-soluble, non-peptidic oligomer (e.g., "POLY" in various structures provided herein) can have any of a number of different geometries. For example, it can be linear, branched, or forked. Most typically, the water-soluble, non-peptidic oligomer is linear or is branched, for example, having one branch point. Although much of the discussion herein is focused upon poly( ethylene oxide) as an illustrative oligomer, the discussion and structures presented herein can be readily extended to encompass any of the water-soluble and non-peptidic oligomers described above.
  • the molecular weight of the oligomer can either be relatively small or relatively large.
  • orally available calcimimetics in unconjugated form
  • exemplary values of the molecular weight of the water-soluble oligomer include: below about 1500; below about 1450; below about 1400; below about 1350; below about 1300; below about 1250; below about 1200; below about 1 150; below about 1 100; below about 1050; below about 1000; below about 950; below about 900; below about 850; below about 800; below about 750; below about 700; below about 650; below about 600; below about 550; below about 500; below about 450; below about 400; below about 350; below about 300; below about 250; below about 200; and below about 100 Daltons.
  • Exemplary ranges of molecular weights of the water-soluble, non-peptidic oligomer include: from about 100 to about 1400 Daltons; from about 100 to about 1200 Daltons; from about 100 to about 800 Daltons; from about 100 to about 500 Daltons; from about 100 to about 400 Daltons; from about 200 to about 500 Daltons; from about 200 to about 400 Daltons; from about 75 to 1000 Daltons; and from about 75 to about 750 Daltons.
  • the number of monomers in the water-soluble, non-peptidic oligomer falls within one or more of the following ranges: between about 1 and about 30 (inclusive); between about 1 and about 25; between about 1 and about 20; between about 1 and about 15; between about 1 and about 12; between about 1 and about 10.
  • the number of monomers in series in the oligomer (and the corresponding conjugate) is one of 1, 2, 3, 4, 5, 6, 7, or 8.
  • the oligomer (and the corresponding conjugate) contains 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 monomers.
  • the oligomer (and the corresponding conjugate) possesses 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 monomers in series.
  • the number of monomers in series in the oligomer falls within one or more of the following ranges: between about 1 and about 30 (inclusive); between about 1 and about 25; between about 1 and about 20; between about 1 and about 15; between about 1 and about 12; between about 1 and about 10.
  • water-soluble and non-peptidic polymer includes CH3-(OCH 2 CH2) n -, "n" is an integer that can be 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30, and can fall within one or more of the following ranges: between about 1 and about 25; between about 1 and about 20; between about 1 and about 15; between about 1 and about 12; between about 1 and about 10.
  • water-soluble, non-peptidic oligomer has 1 , 2, 3, 4, 5, 6, 7, 8, 9, or
  • these values correspond to a methoxy end-capped oligo(ethylene oxide) having a molecular weights of about 75, 1 19, 163, 207, 251 , 295, 339, 383, 427, and 471 Daltons, respectively.
  • these values correspond to methoxy end-capped oligo(ethylene oxide) having molecular weights corresponding to about 515, 559, 603, 647, and 691 Daltons, respectively.
  • the molecular weight of the water-soluble, non-peptidic oligomer, excluding the linker portion, in the compound is relatively large (e.g., greater than 2,000 Daltons), the weight can fall within the range of 2,000 Daltons to about 150,000 Daltons.
  • Exemplary ranges include weight-average molecular weights in the range of from about 3,000 Daltons to about 120,000 Daltons; in the range of from about 5,000 Daltons to about 1 10,000 Daltons; in the range of from greater than 5,000 Daltons to about 100,000 Daltons, in the range of from about 6,000 Daltons to about 90,000 Daltons, in the range of from about 10,000 Daltons to about 85,000 Daltons, in the range of greater than 10,000 Daltons to about 85,000 Daltons, in the range of from about 20,000 Daltons to about 85,000 Daltons, in the range of from about 53,000 Daltons to about 85,000 Daltons, in the range of from about 25,000 Daltons to about 120,000 Daltons, in the range of from about 29,000 Daltons to about 120,000 Daltons, in the range of from about 35,000 Daltons to about 120,000 Daltons, and in the range of from about 40,000 Daltons to about 120,000 Daltons.
  • poly(ethylene oxides) having a molecular weight in one or more of these ranges are preferred.
  • Exemplary weight- average molecular weights for the water-soluble oligomer include about 2,200 Daltons, about 2,500 Daltons, about 3,000 Daltons, about 4,000 Daltons, about 4,400 Daltons, about 4,500 Daltons, about 5,000 Daltons, about 5,500 Daltons, about 6,000 Daltons, about 7,000 Daltons, about 7,500 Daltons, about 8,000 Daltons, about 9,000 Daltons, about 10,000 Daltons, about 1 1 ,000 Daltons, about 12,000 Daltons, about 13,000 Daltons, about 14,000 Daltons, about 15,000 Daltons, about 20,000 Daltons, about 22,500 Daltons, about 25,000 Daltons, about 30,000 Daltons, about 35,000 Daltons, about 40,000 Daltons, about 45,000 Daltons, about 50,000 Daltons, about 55,000 Daltons, about 60,000 Daltons, about 65,000 Daltons, about 70,000 Daltons, and about 75,000 Daltons.
  • Branched versions of the water-soluble oligomer e.g., a branched 40,000 Dalton water-soluble oligomer comprised of two 20,000 Dalton oligomers
  • the conjugate will not have any PEG moieties attached, either directly or indirectly, with a PEG having a weight average molecular weight of less than about 6,000 Daltons.
  • PEGs When used as the polymer, PEGs will typically comprise a number of
  • the number of repeating units is identified by the subscript V in "(OCH 2 CH 2 ) n .”
  • the value of (n) typically falls within one or more of the following ranges: from 2 to about 3400, from about 100 to about 2300, from about 100 to about 2270, from about 136 to about 2050, from about 225 to about 1930, from about 450 to about 1930, from about 1200 to about 1930, from about 568 to about 2727, from about 660 to about 2730, from about 795 to about 2730, from about 795 to about 2730, from about 909 to about 2730, and from about 1 ,200 to about 1,900.
  • the number of repeating units i.e., "n" by dividing the total weight-average molecular weight of the polymer by the molecular weight of
  • the composition containing an activated form of the water-soluble, non-peptidic oligomer be monodisperse.
  • the composition will possess a bimodal distribution centering around any two of the above numbers of monomers.
  • a bimodal oligomer may have any one of the following exemplary combinations of monomer subunits: 1 -2, 1 -3, 1 -4, 1 -5, 1 -6, 1 -7, 1-8, 1 -9, 1 -10, and so forth; 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, and so forth; 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, and so forth; 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, and so forth; 5-6, 5-7, 5-8, 5-9, 5-10, and so forth; 6-7, 6-8, 6-9, 6-10, and so forth; 7-8, 7-9, 7-10, and so forth; and 8-9, 8-10, and so forth.
  • the composition containing an activated form of the water-soluble, non-peptidic oligomer will be trimodal or even tetramodal, possessing a range of monomers units as previously described.
  • Oligomer compositions possessing a well- defined mixture of oligomers i.e., being bimodal, trimodal, tetramodal, and so forth
  • can be prepared by mixing purified monodisperse oligomers to obtain a desired profile of oligomers a mixture of two oligomers differing only in the number of monomers is bimodal; a mixture of three oligomers differing only in the number of monomers is trimodal; a mixture of four oligomers differing only in the number of monomers is tetramodal
  • a desired profile of oligomers a mixture of two oligomers differing only in the number of monomers is bimodal; a mixture of three oligomers differing only in the number of monomers is trimodal; a mixture of four oligomers differing only in the
  • the water-soluble, non-peptidic oligomer is obtained from a composition that is unimolecular or monodisperse. That is, the oligomers in the composition possess the same discrete molecular weight value rather than a distribution of molecular weights.
  • Some monodisperse oligomers can be purchased from commercial sources such as those available from Sigma- Aldrich, or alternatively, can be prepared directly from commercially available starting materials such as Sigma-Aldrich. Water-soluble,
  • non-peptidic oligomers can be prepared as described in Chen Y., Baker, G.L., J. Org. Chem., 6870-6873 (1999), WO 02/098949, and U.S. Patent Application Publication No.
  • the spacer moiety also referred herein as a "linker,” (through which the water-soluble and non-peptidic polymer is attached to the calcimimetic) may be a single bond, a single atom, such as an oxygen atom or a sulfur atom, two atoms, or a number of atoms.
  • a spacer moiety is typically but is not necessarily linear in nature.
  • the spacer moiety, "X,” can be stable or releasable. With respect to enzymes found within living systems, the spacer moiety, "X,” can be stable to such enzymes or releasable upon interaction with such enzymes.
  • the spacer moiety "X" is one having a chain length of less than about 12 atoms, and preferably less than about 10 atoms, and even more preferably less than about 8 atoms and even more preferably less than about 5 atoms, whereby length is meant the number of atoms in a single chain, not counting substituents.
  • the linkage does not comprise further spacer groups.
  • the spacer moiety "X" (or “linkage”) comprises an ether, amide, urethane, amine, thioether, urea, or a carbon-carbon bond. Functional groups such as those discussed below, and illustrated in the examples, are typically used for forming the linkages.
  • the spacer moiety may less preferably also comprise (or be adjacent to or flanked by) other atoms, as described further below,
  • a spacer moiety (or "linkage") of the invention, X may be any of the following: "-" (i.e., a covalent bond, that may be stable or degradable, between the calcimimetic residue and the water-soluble, non-peptidic oligomer), -C(O)0-, -OC(O)-, -CH 2 -C(O)0-, -CH 2 -OC(O)-, -C(O)0-CH 2 -, -OC(O)-CH 2 -, -0-, -NH-, -S- , -C(O)-, C(O)-NH, NH-C(O)-NH, 0-C(O)-NH, -C(S)-, -CH 2 -, -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -CH 2
  • a group of atoms is not considered a linkage when it is immediately adjacent to an oligomer segment, and the group of atoms is the same as a monomer of the oligomer such that the group would represent a mere extension of the oligomer chain.
  • the linkage "X" between the water-soluble, non-peptidic oligomer and the small molecule is typically formed by reaction of a functional group on a terminus of the oligomer (or nascent oligomer when it is desired to "grow" the oligomer onto the
  • an amino group on an oligomer may be reacted with a carboxylic acid or an activated carboxylic acid derivative on the small molecule, or vice versa, to produce an amide linkage.
  • an activated carbonate e.g., succinimidyl or benzotriazyl carbonate
  • reaction of an alcohol (alkoxide) group on an oligomer with an alkyl halide, or halide group within a drug, or vice versa forms an ether linkage.
  • a small molecule having an aldehyde function is coupled to an oligomer amino group by reductive animation, resulting in formation of a secondary amine linkage between the oligomer and the small molecule.
  • a particularly preferred water-soluble, non-peptidic oligomer is an oligomer bearing an aldehyde functional group.
  • the oligomer will have the following structure: CH 3 0-(CH 2 -CH 2 -O) n -(CH 2 ) p -C(O)H, wherein (n) is one of 1 , 2, 3, 4, 5, 6, 7, 8, 9 and 10 and (p) is one of 1 , 2, 3, 4, 5, 6 and 7.
  • Preferred (n) values include 3, 5 and 7 and preferred (p) values 2, 3 and 4.
  • the carbon atom alpha to the -C(O)H moiety can optionally be substituted with alkyl.
  • all but one termini of the water-soluble, non-peptidic oligomer not bearing a functional group is capped to render it unreactive.
  • that group is either selected such that it is unreactive under the conditions of formation of the linkage "X,” or it is protected during the formation of the linkage "X.”
  • the water-soluble, non-peptidic oligomer includes at least one functional group prior to conjugation.
  • the functional group typically comprises an electrophilic or nucleophilic group for covalent attachment to a small molecule, depending upon the reactive group contained within or introduced into the small molecule.
  • nucleophilic groups that may be present in either the oligomer or the small molecule include hydroxyl, amine, hydrazine (-NHN ⁇ ), hydrazide (-C(O)NHNH 2 ), and thiol.
  • Preferred nucleophiles include amine, hydrazine, hydrazide, and thiol, particularly amine.
  • Most small molecule drugs for covalent attachment to an oligomer will possess a free hydroxyl, amino, thio, aldehyde, ketone, or carboxyl group.
  • electrophilic functional groups that may be present in either the oligomer or the small molecule include carboxylic acid, carboxylic ester, particularly imide esters, orthoester, carbonate, isocyanate, isothiocyanate, aldehyde, ketone, thione, alkenyl, acrylate, methacrylate, acrylamide, sulfone, maleimide, disulfide, iodo, epoxy, sulfonate, thiosulfonate, silane, alkoxysilane, and halosilane.
  • succinimidyl ester or carbonate imidazoyl ester or carbonate, benzotriazole ester or carbonate
  • vinyl sulfone chloroethylsulfone
  • vinylpyridine pyridyl disulfide
  • iodoacetamide glyoxal
  • dione mesylate, tosylate, and tresylate (2,2,2-trifluoroethanesulfonate.
  • sulfur analogs of several of these groups such as thione, thione hydrate, thioketal, is 2-thiazolidine thione, etc., as well as hydrates or protected derivatives of any of the above moieties (e.g. aldehyde hydrate, hemiacetal, acetal, ketone hydrate, hemiketal, ketal, thioketal, thioacetal).
  • an "activated derivative" of a carboxylic acid refers to a carboxylic acid derivative that reacts readily with nucleophiles, generally much more readily than the underivatized carboxylic acid.
  • Activated carboxylic acids include, for example, acid halides (such as acid chlorides), anhydrides, carbonates, and esters.
  • esters include imide esters, of the general form -(CO)0-N[(CO)-] 2 ; for example, N-hydroxysuccinimidyl (NHS) esters or N-hydroxyphthalimidyl esters. Also preferred are imidazolyl esters and benzotriazole esters.
  • activated propionic acid or butanoic acid esters are activated propionic acid or butanoic acid esters, as described in co-owned U.S. Patent No. 5,672,662.
  • Other preferred electrophilic groups include succinimidyl carbonate, maleimide, benzotriazole carbonate, glycidyl ether, imidazoyl carbonate, p-nitrophenyl carbonate, acrylate, tresylate, aldehyde, and orthopyridyl disulfide.
  • electrophilic groups are subject to reaction with nucleophiles, e.g., hydroxy, thio, or amino groups, to produce various bond types.
  • Preferred for the present invention are reactions which favor formation of a hydrolytically stable linkage.
  • carboxylic acids and activated derivatives thereof which include orthoesters, succinimidyl esters, imidazolyl esters, and benzotriazole esters, react with the above types of nucleophiles to form esters, thioesters, and amides, respectively, of which amides are the most hydrolytically stable.
  • benzotriazole carbonates react with amino groups to form carbamates.
  • Isocyanates R- C O react with hydroxyl or amino groups to form, respectively, carbamate (RNH-C(O)- OR') or urea (RNH-C(O)-NHR') linkages.
  • Aldehydes, ketones, glyoxals, diones and their hydrates or alcohol adducts i.e., aldehyde hydrate, hemiacetal, acetal, ketone hydrate, hemiketal, and ketal
  • aldehyde hydrate, hemiacetal, acetal, ketone hydrate, hemiketal, and ketal are preferably reacted with amines, followed by reduction of the resulting imine, if desired, to provide an amine linkage (reductive amination).
  • electrophilic functional groups include electrophilic double bonds to which nucleophilic groups, such as thiols, can be added, to form, for example, thioether bonds.
  • nucleophilic groups such as thiols
  • These groups include maleimides, vinyl sulfones, vinyl pyridine, acrylates, methacrylates, and acrylamides.
  • Other groups comprise leaving groups that can be displaced by a nucleophile; these include chloroethyl sulfone, pyridyl disulfides (which include a cleavable S-S bond), iodoacetamide, mesylate, tosylate, thiosulfonate, and tresylate.
  • Epoxides react by ring opening by a nucleophile, to form, for example, an ether or amine bond. Reactions involving complementary reactive groups such as those noted above on the oligomer and the small molecule are utilized to prepare the conjugates of the invention.
  • the calcimimetic may not have a functional group suited for conjugation.
  • the calcimimetic has an amide group, but an amine group is desired, it is possible to modify the amide group to an amine group by way of a Hofmann rearrangement, Curtius
  • a conjugate of a small molecule calcimimetic bearing a hydroxyl group wherein the hydroxyl group-bearing small molecule calcimimetic is coupled to an oligomeric ethylene glycol halide to result in an ether (-0-) linked small molecule conjugate.
  • This can be performed, for example, by using sodium hydride to deprotonate the hydroxyl group followed by reaction with a halide-terminated oligomeric ethylene glycol.
  • a conjugate of a small molecule calcimimetic bearing a hydroxyl group (such as, for example, the calcimimetic having structures encompassed within at least one of Formulae I and II) wherein the hydroxyl group-bearing small molecule calcimimetic is coupled to an oligomeric ethylene glycol bearing an haloformate group [e.g., CH3(OCH 2 CH 2 OC(O)-halo, where halo is chloro, bromo, iodo] to result in an carbonate [-0-C(O)-0-] linked small molecule conjugate.
  • an haloformate group e.g., CH3(OCH 2 CH 2 OC(O)-halo, where halo is chloro, bromo, iodo
  • This can be performed, for example, by combining a calcimimetic and an oligomeric ethylene glycol bearing a haloformate group in the presence of a nucleophilic catalyst (such as 4-dimethylaminopyridine or "DMAP") to thereby result in the corresponding carbonate-linked conjugate.
  • a nucleophilic catalyst such as 4-dimethylaminopyridine or "DMAP"
  • a conjugate of a small molecule calcimimetic bearing an amine group it is possible to prepare a conjugate of a small molecule calcimimetic bearing an amine group.
  • the amine group-bearing small molecule calcimimetic and an aldehyde-bearing oligomer are dissolved in a suitable buffer after which a suitable reducing agent (e.g., NaCNBH 3 ) is added.
  • a suitable reducing agent e.g., NaCNBH 3
  • calcimimetic bearing an amine group, a carboxylic acid-bearing oligomer and the amine group-bearing small molecule calcimimetic are combined, typically in the presence of a coupling reagent (e.g., DCC).
  • a coupling reagent e.g., DCC
  • the result is an amide linkage formed between the amine group of the amine group-containing small molecule calcimimetic and the carbonyl of the carboxylic acid-bearing oligomer.
  • the compounds of the invention may be administered per se or in the form of a pharmaceutically acceptable salt, and any reference to the compounds of the invention herein is intended to include pharmaceutically acceptable salts.
  • a salt of a compound as described herein should be both pharmacologically and pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention.
  • Such pharmacologically and pharmaceutically acceptable salts can be prepared by reaction of the compound with an organic or inorganic acid, using standard methods detailed in the literature.
  • useful salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicyclic, p-toluenesulfonic, tartaric, citric, methanesulfonic, formic, malonic, succinic, naphthalene-2-sulphonic and benzenesulphonic, and the like.
  • pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium, or calcium salts of a carboxylic acid group.
  • an optimally sized oligomer can be identified as by testing a series of compounds, each having a difference oligomer size and the compound having the best activity is identified as a preferred compound.
  • Animal models can also be used to study oral drug transport.
  • non-m vivo methods include rodent everted gut excised tissue and Caco-2 cell monolayer tissue-culture models. These models are useful in predicting oral drug bioavailability.
  • the present invention also includes pharmaceutical preparations comprising a conjugate as provided herein in combination with a pharmaceutical excipient.
  • the conjugate itself will be in a solid form (e.g., a precipitate), which can be combined with a suitable pharmaceutical excipient that can be in either solid or liquid form.
  • Exemplary excipients include, without limitation, those selected from the group consisting of carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof.
  • a carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient.
  • Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose,
  • maltodextrins dextrans, starches, and the like
  • alditols such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like.
  • the excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof.
  • the preparation may also include an antimicrobial agent for preventing or deterring microbial growth.
  • antimicrobial agents suitable for the present invention include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and combinations thereof.
  • An antioxidant can be present in the preparation as well. Antioxidants are used to prevent oxidation, thereby preventing the deterioration of the conjugate or other components of the preparation. Suitable antioxidants for use in the present invention include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium
  • a surfactant may be present as an excipient.
  • exemplary surfactants include: polysorbates, such as “Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (both of which are available from BASF, Mount Olive, New Jersey); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; and chelating agents, such as EDTA, zinc and other such suitable cations.
  • acids or bases may be present as an excipient in the preparation.
  • acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof.
  • Suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
  • the amount of the conjugate in the composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the
  • composition is stored in a unit dose container.
  • a therapeutically effective dose can be determined experimentally by repeated administration of increasing amounts of the conjugate in order to determine which amount produces a clinically desired endpoint.
  • the amount of any individual excipient in the composition will vary depending on the activity of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine
  • excipients will be present in the composition in an amount of about 1 % to about 99% by weight, preferably from about 5%-98% by weight, more preferably from about 15-95% by weight of the excipient, with concentrations less than 30% by weight most preferred.
  • compositions can take any number of forms and the invention is not limited in this regard.
  • Exemplary preparations are most preferably in a form suitable for oral administration such as a tablet, caplet, capsule, gel cap, troche, dispersion, suspension, solution, elixir, syrup, lozenge, transdermal patch, spray, suppository, and powder.
  • Oral dosage forms are preferred for those conjugates that are orally active, and include tablets, caplets, capsules, gel caps, suspensions, solutions, elixirs, and syrups, and can also comprise a plurality of granules, beads, powders or pellets that are optionally
  • Such dosage forms are prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts.
  • Tablets and caplets can be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred when preparing tablets or caplets containing the conjugates described herein.
  • the tablets and caplets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, flow agents, and the like. Binders are used to impart cohesive qualities to a tablet, and thus ensure that the tablet remains intact. Suitable binder materials include, but are not limited to, starch (including corn starch and
  • pregelatinized starch gelatin
  • sugars including sucrose, glucose, dextrose and lactose
  • polyethylene glycol waxes
  • natural and synthetic gums e.g., acacia sodium alginate, polyvinylpyrrolidone, cellulosic polymers (including hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, microcrystalhne cellulose, ethyl cellulose, hydroxyethyl cellulose, and the like), and Veegum.
  • Lubricants are used to facilitate tablet manufacture, promoting powder flow and preventing particle capping (i.e., particle breakage) when pressure is relieved.
  • Useful lubricants are magnesium stearate, calcium stearate, and stearic acid.
  • Disintegrants are used to facilitate disintegration of the tablet, and are generally starches, clays, celluloses, algins, gums, or crosslinked polymers.
  • Fillers include, for example, materials such as silicon dioxide, titanium dioxide, alumina, talc, kaolin, powdered cellulose, and microcrystalhne cellulose, as well as soluble materials such as mannitol, urea, sucrose, lactose, dextrose, sodium chloride, and sorbitol.
  • Stabilizers as well known in the art, are used to inhibit or retard drug decomposition reactions that include, by way of example, oxidative reactions.
  • Capsules are also preferred oral dosage forms, in which case the
  • conjugate-containing composition can be encapsulated in the form of a liquid or gel (e.g., in the case of a gel cap) or solid (including particulates such as granules, beads, powders or pellets).
  • Suitable capsules include hard and soft capsules, and are generally made of gelatin, starch, or a cellulosic material. Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like.
  • parenteral formulations in the substantially dry form typically as a lyophilizate or precipitate, which can be in the form of a powder or cake
  • formulations prepared for injection which are typically liquid and requires the step of reconstituting the dry form of parenteral formulation.
  • suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate-buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.
  • compositions intended for parenteral administration can take the form of nonaqueous solutions, suspensions, or emulsions, each typically being sterile.
  • nonaqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • parenteral formulations described herein can also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • the formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat.
  • the conjugate can also be administered through the skin using conventional transdermal patch or other transdermal delivery system, wherein the conjugate is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin.
  • the conjugate is contained in a layer, or "reservoir,” underlying an upper backing layer.
  • the laminated structure can contain a single reservoir, or it can contain multiple reservoirs.
  • the conjugate can also be formulated into a suppository for rectal
  • the conjugate is mixed with a suppository base material which is (e.g., an excipient that remains solid at room temperature but softens, melts or dissolves at body temperature) such as coca butter (theobroma oil), polyethylene glycols, glycerinated gelatin, fatty acids, and combinations thereof.
  • a suppository base material which is (e.g., an excipient that remains solid at room temperature but softens, melts or dissolves at body temperature)
  • coca butter theobroma oil
  • polyethylene glycols polyethylene glycols
  • glycerinated gelatin glycerinated gelatin
  • fatty acids fatty acids
  • Suppositories can be prepared by, for example, performing the following steps (not necessarily in the order presented): melting the suppository base material to form a melt; incorporating the conjugate (either before or after melting of the suppository base material); pouring the melt into a mold; cooling the melt (e.g., placing the melt-containing mold in a room temperature environment) to thereby form suppositories; and removing the suppositories from the mold.
  • the invention also provides a method for administering a conjugate as provided herein to a patient suffering from a condition that is responsive to treatment with the conjugate.
  • the method comprises administering, generally orally, a therapeutically effective amount of the conjugate (preferably provided as part of a pharmaceutical preparation).
  • Other modes of administration are also contemplated, such as pulmonary, nasal, buccal, rectal, sublingual, transdermal, and parenteral.
  • parenteral includes subcutaneous, intravenous, intra-arterial, intraperitoneal, intracardiac, intrathecal, and intramuscular injection, as well as infusion injections.
  • oligomers In instances where parenteral administration is utilized, it may be necessary to employ somewhat bigger oligomers than those described previously, with molecular weights ranging from about 500 to 30K Daltons (e.g., having molecular weights of about 500, 1000, 2000, 2500, 3000, 5000, 7500, 10000, 15000, 20000, 25000, 30000 or even more).
  • the method of administering may be used to treat any condition that can be remedied or prevented by administration of the particular conjugate.
  • Those of ordinary skill in the art appreciate which conditions a specific conjugate can effectively treat.
  • the actual dose to be administered will vary depend upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered.
  • Therapeutically effective amounts are known to those skilled in the art and/or are described in the pertinent reference texts and literature. Generally, a therapeutically effective amount will range from about 0.001 mg to 1000 mg, preferably in doses from 0.01 mg/day to 750 mg/day, and more preferably in doses from 0.10 mg/day to 500 mg/day.
  • the unit dosage of any given conjugate (again, preferably provided as part of a pharmaceutical preparation) can be administered in a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth.
  • the specific dosing schedule will be known by those of ordinary skill in the art or can be determined
  • Exemplary dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof. Once the clinical endpoint has been achieved, dosing of the composition is halted.
  • mPEGn-N-cinacalcet is prepared using a poly(ethylene glycol) bearing a chloroformate. Schematically, the approach followed for this example is shown below.
  • mPEGn-N-cinacalcet is prepared using a poly( ethylene glycol) bearing a leaving group such as a sulphonate (e.g., mesylate or "Ms") or halide.
  • a sulphonate e.g., mesylate or "Ms”
  • Ms mesylate
  • Cinacalcet is dissolved in DMF. To the solution, NaH is added with stirring.
  • mPEG n -Halide e.g, mPEG n -Br
  • Dichloromethane 150 mL
  • the organic filtrate is washed with water (100 mL x 2) and then dried.
  • the crude product is purified by column chromatography (Si0 2 :
  • mPEGn-N-cinacalcet wherein the oligomer is relatively large is prepared in accordance with the approach described below.
  • compound 1 is prepared using conventional techniques and reacted with tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate obtained from reacting BICIN with t-BOC anhydride in the presence of the coupling agent N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide (or EDC) to yield compound 2.
  • tert-butyl 2-(bis(2-hydroxyethyl)amino)acetate obtained from reacting BICIN with t-BOC anhydride in the presence of the coupling agent N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide (or EDC)
  • compound 3 is treated with 20% trifluoroacetic acid (TFA) to the TFA salt (compound 4).
  • TFA trifluoroacetic acid
  • compound 4 is dissolved in a suitable solvent and a succinimidyl carbonate-terminated mPEG reagent (molecular weight of about 2,000 Daltons) is coupled the base form of compound 4 to yield compound 5.
  • a succinimidyl carbonate-terminated mPEG reagent molecular weight of about 2,000 Daltons
  • This step can alternatively be carried out with a chloroformate-terminated mPEG reagent in place of the succinimidyl carbonate- terminated mPEG rea ent.
  • the carboxylic acid of the carboxylic-containing compound 6 is activated with H-hydroxysuccinimide (NHS) in the presence of a coupling agent to provide compound 7.
  • NHS H-hydroxysuccinimide
  • compound 7 is coupled to the secondary amine of cinacalcet to provide compound
  • the approach is repeated several times in which each time the approach is repeated, a different mPEG weight (e.g., 5,000 Daltons, 10,000 Daltons, 15,000 Daltons, 20,000 Daltons, 30,000 and 40,000 Daltons) is used.
  • a different mPEG weight e.g., 5,000 Daltons, 10,000 Daltons, 15,000 Daltons, 20,000 Daltons, 30,000 and 40,000 Daltons
  • mPEGn-N-cinacalcet wherein the oligomer is relatively large is prepared in accordance with the schematic provided below.
  • compound 9 in which each mPEG has a molecular weight of about 2,000 Daltons is the oligomeric reagent that can be prepared as described in U.S. Patent Application Publication No. 2006/0293499 and can be coupled to cinacalcet to provide compound 10.
  • mPEG weight e.g., mPEG weight of 2,500 Daltons to provide a reagent weight of about 5,000 Daltons, mPEG weight of 5,000 Daltons to provide a reagent weight of about 10,000 Daltons, mPEG weight of about 7,500 Daltons to provide a reagent weight of about 15,000 Daltons, mPEG weight of 10,000 Daltons to provide a reagent weight of about 20,000 Daltons, mPEG weight of about 12,500 Daltons to provide a reagent weight of about 25,000 Daltons, mPEG weight of about 15,000 Daltons to provide a reagent weight of about 30,000 Daltons, and mPEG weight of 20,000 Daltons to provide a reagent weight of about 40,000 Daltons) is used.
  • mPEG weight e.g., mPEG weight of 2,500 Daltons to provide a reagent weight of about 5,000 Daltons, mPEG weight of 5,000 Daltons to provide a reagent weight of about 7,500 Daltons to
  • Cinacalcet can be linked to an oligomer through a spacer moiety (or "linkage") that contains one or more amino acids.
  • a spacer moiety or "linkage” that contains one or more amino acids.
  • a dipeptide can undergo self-cleavage, which represents an extra step in the overall release mechanism and thereby affect the overall release of the active moiety.
  • a compound that includes an amino acid-containing linker between a residue of cinacalcet and an oligomer was prepared following the schematic provided below.
  • Cinacalcet HCl salt (-3.16 g, -8.02 mmol, 11) was dissolved in
  • Cinacalcet free base (-1.0 g, -2.80 mmol, 12), iBoc-glycine (-0.98 g, -5.60 mmol) and 4-N,N-dimethylaminopyridinium 7-tolunesulfonate (DPTS, -0.42 g, -1.40 mmol) were dissolved in dichloromethane. N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide (EDC, -1.3 g, -8.40 mmol) was then added. The reaction mixture was stirred at room temperature overnight (-18 hours).
  • Boc-glycine-amide-cinacalcet (13) (-0.60 g, -1.20 mmol) was dissolved in dichloromethane (-5 mL), and thereafter trifluoroacetic acid (TFA) (-3 mL) was added and the reaction mixture was stirred at room temperature for four hours. The reaction was monitored by HPLC analysis for completion. The dichloromethane product mixture was washed with saturated aqueous Na 2 C0 3 solution twice, dried over Na 2 S0 4 . After removing all solvents, glycine-amide-cinacalcet (14) was obtained as a light-yellow liquid (-0.50 g, ⁇ 1.20 mmol, quantitative yield).
  • a multi-armed oligomer-cinacalcet (also containing an amino acid-containing spacer moiety) was prepared in accordance with the schematic provided below.
  • a compound that includes an amino acid-containing spacer moiety between a residue of cinacalcet and an oligomer was prepared following the schematic provided below.
  • a multi-armed oligomer-cinacalcet (also containing an amino acid-containing spacer moiety) was prepared in accordance with the schematic provided below.
  • a compound that includes an amino acid-containing spacer moiety between a residue of cinacalcet and an oligomer was prepared following the schematic provided below.
  • mPEGio k -CM (-2.3 g, -0.23 mmol), L-valine-acyloxymethyl-carbamate- cinacalcet (23) (-180 mg, -0.33 mmol), triethylamine (TEA, -0.14 mL, -100 mg, -0.99 mmol) and 1 -hydroxybenzotriazole (HOBt, -47 mg, -0.35 mmol) were dissolved in dichloromethane. 7Y-ethyl-7V'-(3-dimethylaminopropyl)carbodiimide (EDC, -0.20 mL, -169 mg, -1.10 mmol) was then added.
  • EDC 7Y-ethyl-7V'-(3-dimethylaminopropyl)carbodiimide
  • a multi-armed oligomer-cinacalcet (also containing an amino acid-containing spacer moiety) was prepared in accordance with the schematic provided below.
  • a compound that includes an amino acid-containing spacer moiety between a residue of cinacalcet and an oligomer was prepared following the schematic provided below.
  • a multi-armed oligomer-cinacalcet (also containing an amino acid-containing spacer moiety) was prepared in accordance with the schematic provided below.
  • FIG. 1A and FIG. IB show the plasma concentration-time profiles (averaged across the four rats) for the tested compounds.
  • FIG. 2 comparisons of the plasma concentration-time profiles for released cinacalcet from each Compound (15) and Compound (16), Examples 5 and 6, respectively, and cinacalcet (unmodified) in DMSO after IV administration. In these two compounds using a glycine-based spacer moiety, only relatively low levels of cinacalcet ( ⁇ 10ng/mL) release could be observed at earlier time points.
  • the exemplary compounds provide a range of dosing options.
  • HEK 293 cells human embryonic kidney cells
  • CaR human parathyroid calcium sensing receptor
  • PEG-Cinacalcet calcimmetic effects were studied in PTH (parathyroid hormone)-lowering experiments in normal rats.
  • Male SD rats ( ⁇ 350g) were IV dosed with different compounds at lmg/kg or orally ("PO") cinacalcet at lOmg/kg.
  • Plasma samples were collected and prepared at different timepoints (up to 72 hours) after drug administration.
  • the plasma PTH levels were quantified by ELISA.
  • Compounds of the invention were tested using this model and are shown to function as calicimimetics.
  • FIG. 6 rat plasma PTH levels after cinacalcet (PO, lOmg/kg) or
  • FIG. 7 rat plasma PTH levels after cinacalcet (PO, l Omg/kg) or
  • Example 14 The approach set forth in Example 14 is repeated except rats are surgically modified to mimic chronic renal insufficiency through the total removal of one kidney and 2/3 of the other kidney (a 5/6 nephrectomy or "5/6Nx"). Each compound is tested over 6-8 weeks following the 5/6 nephrectomy. Parathyroide levels in normal rats are around 100 pg/ml and in 5/6 Nx rats they increase to 500-1000 pg/ml. Compounds of the invention are tested using this model and are shown to function as calicimimetics, with the potential to be used in chronic kidney disease.
  • 5/6 Nx modified rats also mimics parathyroid hyperplasia.
  • compounds of the invention are tested in 5/6 nephrectimized rats and are shown to have potential as decreasing parathyroid hyperplasia (through parathyroid cell proliferation and gland size by removing the parathyroid gland at the end of the study, weighed, sectioned and stained for p21.
  • Example 20
  • Compound 1 can be prepared using the schematic set forth below, wherein reaction conditions of temperature, amounts, time, pH, solvents and the like will be known to one of ordinary skill in the art upon a review of this schematic and the disclosure provided herein.
  • H 2 N-CH 2 CH 2 (OCH 2 CH 2 ) n -OH wherein n is defined as something other than 1 and as otherwise defined herein (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) can be used, to provide (CH 3 )3-OC(O)-NH-CH 2 CH 2 -O(OCH 2 CH 2 ) n -0-CH2-C(O)OH, wherein n is defined as something other than 1 and as otherwise defined herein (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more).

Abstract

L'invention concerne (entre autres) des conjugués oligomère-calcimimétique et des composés apparentés. Un conjugué de l'invention, lorsqu'il est administré par l'une quelconque d'une pluralité de voies d'administration, présente des avantages par rapport aux composés précédemment administrés.
PCT/US2010/050761 2009-09-29 2010-09-29 Conjugués oligomère-calcimimétique et composés associés WO2011056325A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020127005885A KR101828613B1 (ko) 2009-09-29 2010-09-29 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
EP10810996.8A EP2482855B1 (fr) 2009-09-29 2010-09-29 Conjugués oligomère-calcimimétique et composés associés
CA2773353A CA2773353C (fr) 2009-09-29 2010-09-29 Conjugues oligomere-calcimimetique et composes associes
CN201080043400.0A CN102573921B (zh) 2009-09-29 2010-09-29 低聚物-拟钙剂结合物及相关化合物
AU2010315805A AU2010315805B2 (en) 2009-09-29 2010-09-29 Oligomer-calcimimetic conjugates and related compounds
JP2012531124A JP5792175B2 (ja) 2009-09-29 2010-09-29 オリゴマー−カルシミメティクスコンジュゲートおよび関連化合物
MX2012003775A MX341690B (es) 2009-09-29 2010-09-29 Conjugados de oligomero-calciomimetico y compuestos relacionados.
IL218869A IL218869A (en) 2009-09-29 2012-03-27 Oligomer-calcimimetic couplings and preparations containing them
US13/433,100 US8722732B2 (en) 2009-09-29 2012-03-28 Oligomer-calcimimetic conjugates and related compounds
US14/223,572 US9421275B2 (en) 2009-09-29 2014-03-24 Oligomer-calcimimetic conjugates and related compunds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24693109P 2009-09-29 2009-09-29
US61/246,931 2009-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/433,100 Continuation-In-Part US8722732B2 (en) 2009-09-29 2012-03-28 Oligomer-calcimimetic conjugates and related compounds

Publications (2)

Publication Number Publication Date
WO2011056325A2 true WO2011056325A2 (fr) 2011-05-12
WO2011056325A3 WO2011056325A3 (fr) 2011-09-29

Family

ID=43901165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/050761 WO2011056325A2 (fr) 2009-09-29 2010-09-29 Conjugués oligomère-calcimimétique et composés associés

Country Status (9)

Country Link
EP (1) EP2482855B1 (fr)
JP (1) JP5792175B2 (fr)
KR (1) KR101828613B1 (fr)
CN (1) CN102573921B (fr)
AU (1) AU2010315805B2 (fr)
CA (1) CA2773353C (fr)
IL (1) IL218869A (fr)
MX (1) MX341690B (fr)
WO (1) WO2011056325A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105072A (ja) * 2017-03-24 2020-07-09 協和キリン株式会社 ポリエチレングリコール誘導体
WO2020067507A1 (fr) * 2018-09-28 2020-04-02 生化学工業株式会社 Conjugué polysaccharide acide-composé amine primaire ou composé amine secondaire, et son procédé de production
JP7440132B2 (ja) * 2020-09-10 2024-02-28 シャンシー・ミコ・テクノロジー・カンパニー・リミテッド 二重特異性融合ポリペプチド化合物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
WO2002098949A1 (fr) 2001-06-04 2002-12-12 Nobex Corporation Procedes de synthese de melanges sensiblement monodisperses de polymeres contenant des fractions de polyethylene glycol
US20050136031A1 (en) 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules
US20060293499A1 (en) 2005-06-16 2006-12-28 Bentley Michael D Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US7250533B2 (en) 2005-05-16 2007-07-31 Teva Pharmaceutical Industries Ltd Process for preparing Cinacalcet hydrochloride
US7393967B2 (en) 2006-04-27 2008-07-01 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
US7563930B2 (en) 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008233088B2 (en) * 2007-03-30 2013-09-26 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
US11033631B2 (en) * 2008-06-09 2021-06-15 Nektar Therapeutics Methods of treating CYP2D6 alternative metabolizers

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
WO2002098949A1 (fr) 2001-06-04 2002-12-12 Nobex Corporation Procedes de synthese de melanges sensiblement monodisperses de polymeres contenant des fractions de polyethylene glycol
US20050136031A1 (en) 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules
US7250533B2 (en) 2005-05-16 2007-07-31 Teva Pharmaceutical Industries Ltd Process for preparing Cinacalcet hydrochloride
US20060293499A1 (en) 2005-06-16 2006-12-28 Bentley Michael D Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US7563930B2 (en) 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
US7393967B2 (en) 2006-04-27 2008-07-01 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Medical Economics", 1998, article "Physician's Desk Reference"
"Remington: The Science & Practice of Pharmacy", 1995
CHCN Y.; BAKER, G.L., J. ORG. CHEM., 1999, pages 6870 - 6873
KIBBE, A.H.: "Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION
T.W. GREENE; G.M. WUTS: "Protecting Groups in Organic Synthesis", 1999, WILEY

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
US9421275B2 (en) 2009-09-29 2016-08-23 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compunds

Also Published As

Publication number Publication date
MX2012003775A (es) 2012-06-12
CA2773353A1 (fr) 2011-05-12
JP2013505966A (ja) 2013-02-21
CN102573921A (zh) 2012-07-11
MX341690B (es) 2016-08-29
EP2482855B1 (fr) 2017-12-27
IL218869A (en) 2016-12-29
KR101828613B1 (ko) 2018-02-12
CA2773353C (fr) 2018-02-27
JP5792175B2 (ja) 2015-10-07
EP2482855A2 (fr) 2012-08-08
CN102573921B (zh) 2015-11-25
AU2010315805B2 (en) 2015-09-17
KR20120090961A (ko) 2012-08-17
AU2010315805A1 (en) 2012-03-15
WO2011056325A3 (fr) 2011-09-29
IL218869A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
EP2254601B1 (fr) Conjugués d'oligomère et de cannabinoïde
US9233169B2 (en) Oligomer-bis-chromonyl compound conjugates
WO2012083153A1 (fr) Composés comprenant une fraction apremilast et contenant un oligomère
CA2679070A1 (fr) Conjugues d'oligomere antihistaminique
US9399033B2 (en) Oligomer-containing pyrrolidine compounds
CA2773353C (fr) Conjugues oligomere-calcimimetique et composes associes
WO2008112287A1 (fr) Conjugués d'oligomère bêtabloquant
US9168311B2 (en) Oligomer-dantrolene conjugates and related compounds
US20130150441A1 (en) Oligomer-Anticholinergic Agent Conjugates
EP2627639A1 (fr) Aryl-2-oligomère-3-alcoxypropionamides éventuellement substitués en n
US9421275B2 (en) Oligomer-calcimimetic conjugates and related compunds
US10231984B2 (en) Oligomer-foscarnet conjugates
US9487473B2 (en) Oligomer-amino acid conjugates
WO2012082995A1 (fr) Composés d'hydantoïne contenant un oligomère

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080043400.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810996

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010315805

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012531124

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20127005885

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2773353

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010315805

Country of ref document: AU

Date of ref document: 20100929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 218869

Country of ref document: IL

Ref document number: 2818/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/003775

Country of ref document: MX

Ref document number: 2010810996

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE